Author: admin

DelveInsight’s, “COVID-19 Competitive Landscape 2023” report provides comprehensive insights about 400+ COVID-19 Companies and 500+ drugs in Covid-19 Competitive landscape. It covers the COVID-19 therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the COVID-19 Report

• DelveInsight’s COVID-19 report depicts a robust space with 400+ active players working to develop 500+ pipeline therapies for COVID-19 treatment.
• The leading companies working in the COVID-19 Market include Westvac Biopharma, Xenothera, Windtree Therapeutics, Vir Biotechnology, ViiV Healthcare, Verastem, VBL Therapeutics, Vasomune Therapeutics, Inc., Valneva, Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories, UNION Therapeutics, Trustem, Toscana Life Sciences, Throne Biotechnologies, Thirty respiratory Limited, Theravance Biopharma, TC BioPharm, Syntax for Science, S.L, SyneuRx, Swedish Orphan Biovitrum, Swedish Herbal Institute AB, Stemedica Cell Technologies, Staidson (Beijing) Biopharmaceuticals Co., Ltd, Sound Pharmaceuticals, Sorrento Therapeutics, SolAeroMed, SK Bioscience, Sinovac Biotech Co., Ltd, Sinocelltech, Shenzhen Kangtai Biological Products Co., Ltd., Shaperon, Senhwa Biosciences, Inc., Selva Therapeutics, Archivel Farma, R-Pharm, Rohto Pharmaceutical, Revimmune, Resverlogix Corporation, Restorbio, Resolve Therapeutics, Renibus Therapeutics, ReiThera, Regeneron Pharmaceuticals, RedHill Biopharma, Red de Terapia Celular, Reata Pharmaceuticals, Inc., Qurient Co, Quercis Pharma, PureTech, Pulmotect, PTC Therapeutics, Pluristem Ltd., Pliant Therapeutics, Pharming Technologies B.V., Pharmenterprises, Pharmamel S.L., Pharma Holdings, Pharco Pharmaceuticals, Pfizer, Petrovax, Paion UK Ltd., Ashvattha Therapeutics, Inc. (Orpheris), OPKO Health, Oncotelic Inc., National Resilience, Inc. (Ology Bioservices), Olatec Therapeutics LLC, Novavax, Novartis Pharmaceuticals, Notitia Biotechnologies Company, Noorik Biopharmaceuticals, Nobelpharma, Moderna, Moderna, MetrioPharm, Merck Sharp & Dohme Corp., Merck KGaA, Medicago Inc., Mallinckrodt, Mabwell (Shanghai) Bioscience Co., Ltd., Lifefactors Zona Franca, Leading BioSciences, Kiniksa Pharmaceuticals, Ltd., 3M, 4D Pharma, AbbVie, Apotex, AgelessRx, AgenTus Therapeutics, AiCuris, AlloVir, Apeiron Biologics, Bausch Health Americas, BeiGene, Biotest, Bio-Thera Solutions, Cadila Healthcare Limited, Cellenkos, Cellularity Incorporated, Chiesi Farmaceutici S.p.A., Clene Nanomedicine, Codagenix, Debiopharm, Direct Biologics, Eiger BioPharmaceuticals, Emergent Biosolutions, Enlivex Therapeutics, Evergreen Therapeutics, Faron Pharmaceuticals, Frontier Biotechnologies, FSD Pharma, Genentech, Inc., Globavir Biosciences, Grand Medical, Grifols Therapeutics LLC, Inotrem, Ionis Pharmaceuticals, Jazz Pharmaceuticals, Kamada, Kiadis Pharma, Medicine Invention, MedRegen LLC, Miltenyi Biomedicine, Natureceuticals Sdn Bhd, NeoImmune Tech, Neutrolis, Ology Bioservices, Oncovir, OPKO Health, Organicell Regenerative Medicine, and others.
• Promising COVID-19 therapies in the various stages of development includes XAV-19, Sinapultide, VIR-7831, Maraviroc, Duvelisib, VB 201, AV-001, VLA2001, T3 solution for injection, UNIKINON, UNI911, Umbilical cord derived mesenchymal stem cells, MAD0004J08, Stem Cell Educator therapy, RESP301, TD-0903, TCB008, Bemiparin, Pentarlandir™ UPPTA, Emapalumab, Kan Jang capsules, hMSC, BDB-001, Ebselen, COVI-DROPS| Placebo, STI-5656, COVI-AMG, PSC-04, S-1226, GBP510, SARS-COV-2 inactivated vaccine, SCTA01, SARS-CoV-2 Vaccine (Vero Cells), Inactivated, NuSepin, Silmitasertib, SLV213, RUTI® vaccine, Olokizumab + RPH-104, Mesenchymal stem cell (ADR-001), CYT107, Apabetalone, RTB101, RSLV-132, RBT-9, GRAd-COV2, REGN-COV2 Antibody Cocktail, ABC 294640, Upamostat, Mesenchymal Stromal Cells, Bardoxolone methyl, Telacebec, IQC-950AN, LYT-100, PUL-042, PTC-299, PLX-PAD, PLN-74809, Conestat alfa, Treamid, Melatonin, LTX-109, Selenium, Ramipril, PF-06650833, Polyoxidonium, Remimazolam, OP-101, Rayaldee, OT-101, ADM03820, OLT 1177, NVXCoV 2373, DFV890, Crizanlizumab, MAS-825, NBT-NM108, Ambrisentan, Sargramostim, Gam-COVID-Vac, mRNA-1283, mRNA-1273, MP1032, Molnupiravir, M5049, Covifenz, INOmax, MW33, COVID-19 convalescent plasma, LB1148, Mavrilimumab, and others.
• November 2023: AstraZeneca announced a study of Phase 3 clinical trials for AZD7442. This study will assess the efficacy of AZD7442 for the post-exposure prophylaxis of COVID-19 in Adults.
• November 2023: BioNTech SE announced a study of Phase 1 clinical trials for BNT162b4 5 µg. The trial will use a staggered dosing process schema, i.e., enrollment into the next higher dose level is done sequentially and subject to safety data from the previous dose levels, with sentinel participants in Cohorts 1, 2, 3a, and 4a. Cohort 3b investigating the same dose level as Cohort 3a but in participants aged >55 years will be opened after safety data for participants aged 18-55 years in Cohort 3a has been reviewed.

Request a sample and discover the recent advances in COVID-19 Drugs @ COVID-19 Competitive Landscape Report

The COVID-19 report provides an in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the COVID-19 report which provides company-company collaboration (licensing/partnering), company academic collaboration, and acquisition analysis in tabulated form.

COVID-19 Overview

Coronaviruses are a large family of viruses that can cause illness in animals or humans. In humans several known coronaviruses cause respiratory infections. These coronaviruses range from the common cold to more severe diseases such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and COVID-19.

Find out more about COVID-19 Analytical Perspective: In-depth Commercial Assessment @ COVID-19 Collaboration Analysis by Companies

COVID-19 Companies and Therapies

• Nobelpharma: Sargramostim
• Staidson (Beijing) Biopharmaceuticals Co., Ltd: BDB-001
• NeuroActiva Inc.: NA-831
• Nanogen Pharmaceutical Biotechnology: Nanocovax

COVID-19 Competitive Landscape

The COVID-19 report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

COVID-19 Report Assessment

• Company Analysis
• COVID-19 Therapeutic Assessment
• COVID-19 Pipeline Assessment
• Inactive drugs assessment
• COVID-19 Unmet Needs

Learn more about the emerging COVID-19 Competitive Landscape @ COVID-19 Market Drivers and Barriers, Unmet Needs

Scope of the COVID-19 Report

• Coverage- Global
• COVID-19 Therapeutics Assessment: Product Type, Stage and Product Type, Route of Administration, Molecule Type
• COVID-19 Companies- Westvac Biopharma, Xenothera, Windtree Therapeutics, Vir Biotechnology, ViiV Healthcare, Verastem, VBL Therapeutics, Vasomune Therapeutics, Inc., Valneva, Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories, UNION Therapeutics, Trustem, Toscana Life Sciences, Throne Biotechnologies, Thirty respiratory Limited, Theravance Biopharma, TC BioPharm, Syntax for Science, S.L, SyneuRx, Swedish Orphan Biovitrum, Swedish Herbal Institute AB, Stemedica Cell Technologies, Staidson (Beijing) Biopharmaceuticals Co., Ltd, Sound Pharmaceuticals, Sorrento Therapeutics, SolAeroMed, SK Bioscience, Sinovac Biotech Co., Ltd, Sinocelltech, Shenzhen Kangtai Biological Products Co., Ltd., Shaperon, Senhwa Biosciences, Inc., Selva Therapeutics, Archivel Farma, R-Pharm, Rohto Pharmaceutical, Revimmune, Resverlogix Corporation, Restorbio, Resolve Therapeutics, Renibus Therapeutics, ReiThera, Regeneron Pharmaceuticals, RedHill Biopharma, Red de Terapia Celular, Reata Pharmaceuticals, Inc., Qurient Co, Quercis Pharma, PureTech, Pulmotect, PTC Therapeutics, Pluristem Ltd., Pliant Therapeutics, Pharming Technologies B.V., Pharmenterprises, Pharmamel S.L., Pharma Holdings, Pharco Pharmaceuticals, Pfizer, Petrovax, Paion UK Ltd., Ashvattha Therapeutics, Inc. (Orpheris), OPKO Health, Oncotelic Inc., National Resilience, Inc. (Ology Bioservices), Olatec Therapeutics LLC, Novavax, Novartis Pharmaceuticals, Notitia Biotechnologies Company, Noorik Biopharmaceuticals, Nobelpharma, Moderna, Moderna, MetrioPharm, Merck Sharp & Dohme Corp., Merck KGaA, Medicago Inc., Mallinckrodt, Mabwell (Shanghai) Bioscience Co., Ltd., Lifefactors Zona Franca, Leading BioSciences, Kiniksa Pharmaceuticals, Ltd., 3M, 4D Pharma, AbbVie, Apotex, AgelessRx, AgenTus Therapeutics, AiCuris, AlloVir, Apeiron Biologics, Bausch Health Americas, BeiGene, Biotest, Bio-Thera Solutions, Cadila Healthcare Limited, Cellenkos, Cellularity Incorporated, Chiesi Farmaceutici S.p.A., Clene Nanomedicine, Codagenix, Debiopharm, Direct Biologics, Eiger BioPharmaceuticals, Emergent Biosolutions, Enlivex Therapeutics, Evergreen Therapeutics, Faron Pharmaceuticals, Frontier Biotechnologies, FSD Pharma, Genentech, Inc., Globavir Biosciences, Grand Medical, Grifols Therapeutics LLC, Inotrem, Ionis Pharmaceuticals, Jazz Pharmaceuticals, Kamada, Kiadis Pharma, Medicine Invention, MedRegen LLC, Miltenyi Biomedicine, Natureceuticals Sdn Bhd, NeoImmune Tech, Neutrolis, Ology Bioservices, Oncovir, OPKO Health, Organicell Regenerative Medicine, and others.
• COVID-19 therapies- XAV-19, Sinapultide, VIR-7831, Maraviroc, Duvelisib, VB 201, AV-001, VLA2001, T3 solution for injection, UNIKINON, UNI911, Umbilical cord derived mesenchymal stem cells, MAD0004J08, Stem Cell Educator therapy, RESP301, TD-0903, TCB008, Bemiparin, Pentarlandir™ UPPTA, Emapalumab, Kan Jang capsules, hMSC, BDB-001, Ebselen, COVI-DROPS| Placebo, STI-5656, COVI-AMG, PSC-04, S-1226, GBP510, SARS-COV-2 inactivated vaccine, SCTA01, SARS-CoV-2 Vaccine (Vero Cells), Inactivated, NuSepin, Silmitasertib, SLV213, RUTI® vaccine, Olokizumab + RPH-104, Mesenchymal stem cell (ADR-001), CYT107, Apabetalone, RTB101, RSLV-132, RBT-9, GRAd-COV2, REGN-COV2 Antibody Cocktail, ABC 294640, Upamostat, Mesenchymal Stromal Cells, Bardoxolone methyl, Telacebec, IQC-950AN, LYT-100, PUL-042, PTC-299, PLX-PAD, PLN-74809, Conestat alfa, Treamid, Melatonin, LTX-109, Selenium, Ramipril, PF-06650833, Polyoxidonium, Remimazolam, OP-101, Rayaldee, OT-101, ADM03820, OLT 1177, NVXCoV 2373, DFV890, Crizanlizumab, MAS-825, NBT-NM108, Ambrisentan, Sargramostim, Gam-COVID-Vac, mRNA-1283, mRNA-1273, MP1032, Molnupiravir, M5049, Covifenz, INOmax, MW33, COVID-19 convalescent plasma, LB1148, Mavrilimumab, and others.

Dive deep into rich insights for new drugs for COVID-19 Product Developmental Activities, Visit @ COVID-19 Research and Development Activities

Table of Content

1. Introduction
2. Executive Summary
3. COVID-19: Overview
4. COVID-19 -Analytical Perspective: In-depth Commercial Assessment
5. Competitive Landscape
6. Therapeutic Assessment
7. COVID-19: Company and Product Profiles (Marketed Therapies)
8. AstraZeneca
9. AZD1222
10. COVID-19: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Phase III)
12. Vicore Pharma
13. C21
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II)
16. Company Name
17. Product Name
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. Enanta Pharmaceuticals
21. EDP 235
22. Drug profiles in the detailed report…..
23. Preclinical and Discovery Stage Products
24. Company Name
25. Product Name
26. Drug profiles in the detailed report…..
27. Inactive Products
28. COVID-19- Unmet needs
29. COVID-19 – Market drivers and barriers
30. Appendix

For further information on the COVID-19 Report @ COVID-19 Preclinical and Discovery Stage Products

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/hypertriglyceridemia-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: COVID-19 Competitive Landscape (Updated) | Westvac Biopharma, Xenothera, Windtree Therapeutics, Vir Biotechnology, ViiV Healthcare, Verastem, VBL Therapeutics, Vasomune Therapeutics, and others.

DelveInsight’s, “Acute Myeloid Leukemia Pipeline Insight 2023” report provides comprehensive insights about 260+ companies and 260+ pipeline drugs in the Acute Myeloid Leukemia pipeline landscape. It covers the Acute Myeloid Leukemia pipeline drug profiles, including Acute Myeloid Leukemia clinical trials and nonclinical stage products. It also covers the Acute Myeloid Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Acute Myeloid Leukemia Pipeline Report

• DelveInsight’s Acute Myeloid Leukemia pipeline report depicts a robust space with 260+ active players working to develop 260+ pipeline therapies for Acute Myeloid Leukemia treatment.
• The leading companies working in the Acute Myeloid Leukemia market include GlycoMimetics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Takeda Oncology, Orca Bio, Gilead Sciences, Actinium Pharmaceuticals, Kronos Bio, Bristol-Myers Squibb, ImmunityBio, Bellicum Pharmaceuticals, TC BioPharm, Syros Pharmaceuticals, Armaceutica, Teva Pharmaceutical Industries, New Epsilon Innovation Limited, MediGene, TC Biopharm, PersonGen BioTherapeutics, Oncoceutics, Janssen Research & Development, LLC, Immune-Onc Therapeutics, Novartis, Jasper Therapeutics, Agastiya Biotech, Poseida Therapeutics, Molecular Partners, Allogene Therapeutics, Allogene therapeutics, and others.
• Promising Acute Myeloid Leukemia Pipeline Therapies in the various stages of development include OCV-501, SEL24/MEN1703, Venetoclax, Alvocidib, TL-895, KRT-232, XY0206, Azacitidine, Venetoclax, and others.
• On February 2023, Telios Pharma Inc. announced a study of Phase 1 & 2 clinical trials for TL-895 and KRT-232. This study evaluates TL-895, a potent, orally available and highly selective irreversible tyrosine kinase inhibitor combined with navtemadlin (KRT-232), a novel oral small molecule inhibitor of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refractory (e.g., having failed prior therapy) to be eligible for this study.
• On May 2023, Menarini Group announced a study of Phase 1 & 2 clinical trials for SEL24/MEN1703. The purpose of the clinical trial is to identify the maximum tolerated dose of SEL24/MEN1703 and to further investigate its safety profile in patients with Acute Myeloid Leukemia.
• On May 2023, Shijiazhuang Yiling Pharmaceutical Co. Ltd announced a study of Phase 1 clinical trials for XY0206. To evaluate the safety and tolerability of xy0206 as single drug in the treatment of relapsed / refractory AML.
• On July 2023, AbbVie announced a study of Phase 3 clinical trials for Azacitidine, and Venetoclax. Participants will continue to have study visits and receive treatment for as long as they are having a clinical benefit. The effect of the treatment on AML will be checked by taking blood, bone marrow, scans, measuring side effects and by completing health questionnaires.

Request a sample and discover the recent advances in Acute Myeloid Leukemia Treatment Drugs @ Acute Myeloid Leukemia Infection Pipeline Report

The Acute Myeloid Leukemia pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Acute Myeloid Leukemia drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Acute Myeloid Leukemia clinical trial landscape.

Acute Myeloid Leukemia Overview

Acute myeloid leukemia (AML) is the most common leukemia among the adult population and accounts for about 80% of all cases. It is characterized by clonal expansion of immature “blast cells” in the peripheral blood and bone marrow resulting in ineffective erythropoiesis and bone marrow failure.

Find out more about Acute Myeloid Leukemia Treatment Drugs @ Drugs for Acute Myeloid Leukemia Treatment

Acute Myeloid Leukemia Emerging Drugs Profile

• Omidubicel: Gamida Cell
• Uproleselan: GlycoMimetics
• ALT 803: ImmunityBio
• BPX-501: Bellicum Pharmaceuticals

 Acute Myeloid Leukemia Pipeline Therapeutics Assessment

There are approx. 260+ key companies which are developing the Acute Myeloid Leukaemia therapies. The Acute Myeloid Leukaemia companies which have their Acute Myeloid Leukaemia drug candidates in the most advanced stage, i.e preregistration include Gamida Cell.

DelveInsight’s Acute Myeloid Leukemia pipeline report covers around 260+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

The Acute Myeloid Leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Acute Myeloid Leukaemia Pipeline Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Acute Myeloid Leukemia Pipeline Therapies @ Acute Myeloid Leukemia Clinical Trials Assessment

Scope of the Acute Myeloid Leukemia Pipeline Report

• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Acute Myeloid Leukemia Companies- GlycoMimetics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Takeda Oncology, Orca Bio, Gilead Sciences, Actinium Pharmaceuticals, Kronos Bio, Bristol-Myers Squibb, ImmunityBio, Bellicum Pharmaceuticals, TC BioPharm, Syros Pharmaceuticals, Armaceutica, Teva Pharmaceutical Industries, New Epsilon Innovation Limited, MediGene, TC Biopharm, PersonGen BioTherapeutics, Oncoceutics, Janssen Research & Development, LLC, Immune-Onc Therapeutics, Novartis, Jasper Therapeutics, Agastiya Biotech, Poseida Therapeutics, Molecular Partners, Allogene Therapeutics, Allogene therapeutics, and others.
• Acute Myeloid Leukemia Pipeline Therapies- OCV-501, SEL24/MEN1703, Venetoclax, Alvocidib, TL-895, KRT-232, XY0206, Azacitidine, Venetoclax, and others.

Dive deep into rich insights for new drugs for Acute Myeloid Leukemia treatment, Visit @ Acute Myeloid Leukemia Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Executive Summary
3. Acute Myeloid Leukaemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Acute Myeloid Leukaemia– DelveInsight’s Analytical Perspective
7. Late Stage Products (Preregistration)
8. Omidubicel: Gamida Cell
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase III)
11. Uproleselan: GlycoMimetics
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. ALT 803: ImmunityBio
15. Early Stage Products (Phase I)
16. JNJ-75276617: Janssen Research & Development, LLC
17. Drug profiles in the detailed report…..
18. Preclinical Stage Products
19. AB001: Agastiya Biotech
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Acute Myeloid Leukaemia Key Companies
23. Acute Myeloid Leukaemia Key Products
24. Acute Myeloid Leukaemia- Unmet Needs
25. Acute Myeloid Leukaemia- Market Drivers and Barriers
26. Acute Myeloid Leukaemia- Future Perspectives and Conclusion
27. Acute Myeloid Leukaemia Analyst Views
28. Acute Myeloid Leukaemia Key Companies
29. Appendix

For further information on the Acute Myeloid Leukemia pipeline therapeutics, reach out @ Acute Myeloid Leukemia Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/hypertriglyceridemia-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Myeloid Leukemia Pipeline Report | GlycoMimetics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Takeda Oncology, Orca Bio, Gilead Sciences, and others.

DelveInsight’s, “CAR T Cell Therapy Competitive Landscape 2023” report provides comprehensive insights about 250+ CAR-T Cell Therapy companies and 500+ drugs in CAR T – Cell Therapy Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the CAR-T Cell Therapy Report

• DelveInsight’s CAR-T Cell Therapy report depicts a robust space with 250+ active players working to develop 500+ pipeline therapies for CAR-T Cell Therapy treatment.
• The leading companies working in the CAR-T Cell Therapy Market include Cartesian Therapeutics, CASI Pharmaceuticals, Juventas Cell Therapy, Novartis, Poseida Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, JW Therapeutics, Gilead Sciences, Cellular Biomedicine Group, Gracell Bio, Mustang Bio, Servier, iCell Gene Therapeutics, Kecellitics Biotech Company Ltd, Gilead sciences, Miltenyi Biotech, Nanjing KAEDI Biotech, Liminatus Pharma, Yake Biotechnology, AffyImmune Therapeutics, Fundamenta Therapeutics, Actinium Pharmaceuticals, Allogene Therapeutics, Celyad Oncology, Maxcyte, Sorrento Therapeutics, Cellular Biomedicine Group, Sorrento Therapeutics, Shanghai GeneChem Co., Ltd., Sensei Biotherapeutics, Obsidian Therapeutics, Beijing Biohealthcare Biotechnology Co. Ltd. , Eutilex/Utilities, Precigen, Inc., Miltenyi Biomedicine, Wugen, WindMIL Therapeutics, MiNK Therapeutics, CiMaas, Catamaran Bio, Innate Pharma, Healios, Chimeric Therapeutics, ONK Therapeutics, Neukio Biotherapeutics, Exacis Biotherapeutics, Editas Medicine, and others.
• Promising CAR-T Cell Therapy Therapies in the various stages of development include Relmacabtagene autoleucel, KTE-X19, Abecma, Zevorcabtagene autoleucel, Descartes 011, AUTO8, SG299, and others.
• December 2023: Peter MacCallum Cancer Centre, Australia announced a study of phase 1 clinical trials for JNJ-68284528 (Cilta-cel) & 64Cu SPION dual PET-MR imaging agent. This clinical trial will investigate the in vivo trafficking of cilta-cel in extramedullary myeloma using 64Cu Super Paramagnetic Iron Oxide Nanoparticle (64Cu SPION) and Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI).
• December 2023: University of Pennsylvania announced a study of Phase 2 clinical trials for Cevostamab. This is a Phase 2, open-label, single-arm, single stage, single-institution study, with an initial safety run-in period. Potential participants with relapsed/refractory myeloma who are undergoing standard of care, commercially-available BCMA-directed CAR T cell therapy may be identified pre-CAR T cell infusion but are not consented and enrolled until at least 4-6 weeks after CAR T cell infusion, once recovered from acute toxicities.

Request a sample and discover the recent advances in CAR-T Cell Therapy Drugs @ CAR-T Cell Therapy Competitive Landscape Report

The CAR-T Cell Therapy report provides an in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing, and acquisition – deal values trends. The sub-segmentation is described in the CAR-T Cell Therapy report which provides company-company collaboration (licensing/partnering), company academic collaboration, and acquisition analysis in tabulated form.

CAR-T Cell Therapy Overview

CAR T-cells are the fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signaling domains. A CAR combines antigen-binding domains-most commonly, a single-chain variable fragment (scFv) derived from the variable domains of antibodies with the signaling domains of the TCR chain and additional costimulatory domains from receptors, such as CD28, OX40, and CD137.

Find out more about CAR-T Cell Therapy Analytical Perspective: In-depth Commercial Assessment @ CAR-T Cell Therapy Collaboration Analysis by Companies

CAR-T Cell Therapy Companies and Therapies

• CARsgen: Zevorcabtagene autoleucel
• Cartesian Therapeutics: Descartes 011
• Autolus Therapeutics PLC: AUTO8
• Sana Biotechnology: SG299

CAR T- Cell Therapy Competitive Landscape

The CAR-T Cell Therapy competitive landscape report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

CAR T- Cell Therapy Report Assessment

• CAR T-Cell Therapy Company Analysis
• CAR T-Cell Therapy Therapeutic Assessment
• CAR T- Cell Therapy Pipeline Assessment
• CAR T-Cell Therapy Inactive Drugs Assessment
• CAR T-Cell Therapy Unmet Needs

Learn more about the emerging CAR-T Cell Therapy Competitive Landscape @ CAR-T Cell Therapy Market Drivers and Barriers, Unmet Needs

Scope of the CAR-T Cell Therapy Report

• Coverage- Global
• CAR-T Cell Therapy Therapeutics Assessment: Product Type, Stage and Product Type, Route of Administration, Molecule Type
• CAR-T Cell Therapy Companies- Cartesian Therapeutics, CASI Pharmaceuticals, Juventas Cell Therapy, Novartis, Poseida Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, JW Therapeutics, Gilead Sciences, Cellular Biomedicine Group, Gracell Bio, Mustang Bio, Servier, iCell Gene Therapeutics, Kecellitics Biotech Company Ltd, Gilead sciences, Miltenyi Biotech, Nanjing KAEDI Biotech, Liminatus Pharma, Yake Biotechnology, AffyImmune Therapeutics, Fundamenta Therapeutics, Actinium Pharmaceuticals, Allogene Therapeutics, Celyad Oncology, Maxcyte, Sorrento Therapeutics, Cellular Biomedicine Group, Sorrento Therapeutics, Shanghai GeneChem Co., Ltd., Sensei Biotherapeutics, Obsidian Therapeutics, Beijing Biohealthcare Biotechnology Co. Ltd. , Eutilex/Utilities, Precigen, Inc., Miltenyi Biomedicine, Wugen, WindMIL Therapeutics, MiNK Therapeutics, CiMaas, Catamaran Bio, Innate Pharma, Healios, Chimeric Therapeutics, ONK Therapeutics, Neukio Biotherapeutics, Exacis Biotherapeutics, Editas Medicine, and others.
• CAR-T Cell Therapy Therapies- Relmacabtagene autoleucel, KTE-X19, Abecma, Zevorcabtagene autoleucel, Descartes 011, AUTO8, SG299, and others.

Dive deep into rich insights for new drugs for CAR-T Cell Therapy Product Developmental Activities, Visit @ CAR-T Cell Therapy Research and Development Activities

Table of Content

1. Introduction
2. Executive Summary
3. CAR T – Cell Therapy: Overview
4. CAR T – Cell Therapy-Analytical Perspective: In-depth Commercial Assessment
5. Competitive Landscape
6. Therapeutic Assessment
7. CAR T – Cell Therapy: Company and Product Profiles (Marketed Therapies)
8. JW Therapeutics
9. Relmacabtagene autoleucel
10. Oncolytic Virus Cancer Therapy: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Registered)
12. CARsgen
13. Zevorcabtagene autoleucel
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II)
16. Cartesian Therapeutics
17. Descartes 011
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. Autolus Therapeutics
21. AUTO-8
22. Drug profiles in the detailed report…..
23. Preclinical and Discovery Stage Products
24. Sana Biotechnology
25. SG299
26. Drug profiles in the detailed report…..
27. Inactive Products
28. CAR T – Cell Therapy – Unmet needs
29. CAR T – Cell Therapy– Market drivers and barriers
30. Appendix

For further information on the CAR-T Cell Therapy Report @ CAR-T Cell Therapy Preclinical and Discovery Stage Products

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/hypertriglyceridemia-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CAR-T Cell Therapy Competitive Landscape (Updated) | CASI Pharmaceuticals, Juventas Cell Therapy, Novartis, Poseida Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, and others.

DelveInsight’s, “Gene Therapy Competitive Landscape 2023” report provides comprehensive insights about 250+ Gene Therapy companies and 300+ Gene Therapy drugs in the Gene therapy Competitive landscape. It covers the Gene Therapy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Gene Therapy Competitive Landscape Report

• DelveInsight’s Gene Therapy report depicts a robust space with 250+ active players working to develop 300+ pipeline therapies for Gene Therapy treatment.
• The leading companies working in the Gene Therapy Market include Candel Therapeutics, SillaJen Biotherapeutics, Wuhan Binhui Biotechnology, Virogin Biotech, Replimune, Istari Oncology, Immvira Pharma, Lokon Pharma, ORCA Therapeutics, Beijing SyngenTech, Tasly Pharmaceuticals, Turnstone Biologics, BioInvent, Transgene, Elicera Therapeutics, Orgenesis, Virttu Biologics, Imugene, Astellas Pharma, Mustang Bio, Virogin Biotech, Memgen, Replimune, Immvira Pharma, PsiOxus Therapeutics, VCN Biosciences, Sorrento Therapeutics, Calidi Biotherapeutics, Replimune, TILT Biotherapeutics, DNAtrix, and others.
• Promising Gene Therapy Therapies in the various stages of development include ABECMA, ADSTILADRIN, ALLOCOR, BREYANZI, CARVYKTI, CLEVECORD, Ducord, HPC Cord Blood, GINTUIT and others.
• December 2023: Sangamo Therapeutics announced a study of Phase 1 & 2 clinical trials for ST-920. This is the first in human treatment with ST-920, a recombinant AAV2/6 vector encoding the cDNA for human a-Gal A. The purpose of this study is to evaluate the safety and tolerability of ascending doses of ST-920. ST-920 aims to provide stable, long-term production of α-Gal A at therapeutic levels in subjects with Fabry disease. The constant production of α-Gal A in humans should, importantly, enable reduction and potentially clearance of Fabry disease substrates Gb3 and lyso-Gb3.
• December 2023: Regenxbio Inc. announced a study of Phase 1 & 2 clinical trials for RGX-202. RGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain. This is a multicenter, open-label dose evaluation clinical study to assess the safety, tolerability and clinical efficacy of a one-time intravenous (IV) dose of RGX-202 in participants with Duchenne.

Request a sample and discover the recent advances in Gene Therapy @ Gene Therapy Competitive Landscape Report

The Gene Therapy report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the Gene Therapy report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

Gene Therapy Overview

Gene therapy is a technique that uses a gene(s) to treat, prevent or cure a disease or medical disorder. Often, gene therapy works by adding new copies of a gene that is broken, or by replacing a defective or missing gene in a patient’s cells with a healthy version of that gene. Both inherited genetic diseases (e.g., hemophiliaand sickle cell disease) and acquired disorders (e.g., leukemia) have been treated with gene therapy.

Find out more about Gene Therapy Analytical Perspective: In-depth Commercial Assessment @ Gene Therapy Collaboration Analysis by Companies

Gene Therapy Companies and Therapies

• Candel Therapeutics: CAN-2409
• CRISPR Therapeutics: CTX001
• TILT Biotherapeutics: TILT-123
• Akamis Bio: NG-347

Gene Therapy Competitive Landscape

The Gene Therapy report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

Gene Therapy Pipeline Report Assessment

• Gene Therapy Company Analysis
• Gene Therapy Therapeutic Assessment
• Gene Therapy Pipeline Assessment
• Gene Therapy Inactive drugs assessment
• Gene Therapy Unmet Needs

Learn more about the emerging Gene Therapy Competitive Landscape @ Gene Therapy Market Drivers and Barriers, Unmet Needs

Scope of the Gene Therapy Report

• Coverage- Global
• Gene Therapy Therapeutics Assessment: Product Type, Stage and Product Type, Route of Administration, Molecule Type
• Gene Therapy Companies- Candel Therapeutics, SillaJen Biotherapeutics, Wuhan Binhui Biotechnology, Virogin Biotech, Replimune, Istari Oncology, Immvira Pharma, Lokon Pharma, ORCA Therapeutics, Beijing SyngenTech, Tasly Pharmaceuticals, Turnstone Biologics, BioInvent, Transgene, Elicera Therapeutics, Orgenesis, Virttu Biologics, Imugene, Astellas Pharma, Mustang Bio, Virogin Biotech, Memgen, Replimune, Immvira Pharma, PsiOxus Therapeutics, VCN Biosciences, Sorrento Therapeutics, Calidi Biotherapeutics, Replimune, TILT Biotherapeutics, DNAtrix, and others.
• Gene Therapy Therapies- ABECMA, ADSTILADRIN, ALLOCOR, BREYANZI, CARVYKTI, CLEVECORD, Ducord, HPC Cord Blood, GINTUIT and others.

Dive deep into rich insights for new drugs for Gene Therapy Product Developmental Activities, Visit @ Gene Therapy Research and Development Activities

Table of Content

1. Introduction
2. Executive Summary
3. Gene Therapy: Overview
4. Gene Therapy -Analytical Perspective: In-depth Commercial Assessment
5. Competitive Landscape
6. Therapeutic Assessment
7. Gene Therapy: Company and Product Profiles (Marketed Therapies)
8. Juno Therapeutics, Inc./Bristol-Myers Squibb
9. BREYANZI
10. Gene Therapy: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Phase III)
12. Candel Therapeutics
13. CAN-2409
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II)
16. Company Name
17. Product Name
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. TILT Biotherapeutics
21. TILT-123
22. Drug profiles in the detailed report…..
23. Preclinical and Discovery Stage Products
24. Company Name
25. Product Name
26. Drug profiles in the detailed report…..
27. Inactive Products
28. Gene Therapy- Unmet needs
29. Gene Therapy – Market drivers and barriers
30. Appendix

For further information on the Gene Therapy Report @ Gene Therapy Preclinical and Discovery Stage Products

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/hypertriglyceridemia-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gene therapy Competitive Landscape Report (Updated) | Candel Therapeutics, SillaJen Biotherapeutics, Wuhan Binhui Biotechnology, Virogin Biotech, Replimune, and others.

DelveInsight’s, “Bispecific antibody Competitive landscape, 2023,” report provides comprehensive insights about 250+ Bispecific Antibody companies and 300+ Bispecific Antibody drugs in Bispecific antibody Competitive landscape. It covers the Bispecific Antibody therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Bispecific Antibody Competitive Landscape Report

• DelveInsight’s Bispecific Antibody report depicts a robust space with 250+ active players working to develop 300+ pipeline therapies for Bispecific Antibody treatment.
• The leading companies working in the Bispecific Antibody Competitive landscape include Janssen, Amgen, Akeso, Zymeworks, Roche, IGM Biosciences, MacroGenics, Provention Bio, Jiangsu Alphamab Biopharmaceuticals, Sichuan Baili Pharmaceutical, Regeneron Pharmaceuticals, Boehringer Ingelheim, and others.
• Promising Bispecific Antibody Therapies in the various stages of development include SI-B003, AK104, Bevacizumab, Paclitaxel, AK112, LY3434172, CDX-527, Etoposide, Carboplatin, and others.
• December 2023: Hoffmann-La Roche, An Open Label, Multicenter, Dose Escalation, Phase 1 & 2 Clinical Study to Evaluate Safety/Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-Tumor Activity of RO7247669, a PD1-LAG3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors.
• December 2023: Janssen Research & Development Inc. announced a study of Phase 1 clinical trials for Teclistamab (IV). The purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for Teclistamab and to characterize the safety and tolerability of Teclistamab at the RP2Ds.

Request a sample and discover the recent advances in Bispecific Antibody Drugs @ Bispecific Antibody Competitive Landscape Report

The Bispecific Antibody competitive landscape report provides an in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing, and acquisition – deal values trends. The sub-segmentation is described in the Bispecific Antibody report which provides company-company collaboration (licensing/partnering), company academic collaboration, and acquisition analysis in tabulated form.

Bispecific Antibody Overview

Immunoglobulins (antibodies [Abs]) are major protein components of the adaptive immune system, directed against foreign compounds and infectious agents. The IgG molecule consists of two light and two heavy chains connected by disulfide bonds; IgG is a monomer with a molecular weight of 146–160 kDa. Antigen-binding centers of Abs are formed by hypervariable regions of heavy and light chains. In the classical point of view, the Ab molecule contains two identical antigen-binding sites (two HL fragments) and is monospecific and bivalent.

Find out more about Bispecific Antibody Analytical Perspective: In-depth Commercial Assessment @ Bispecific Antibody Collaboration Analysis by Companies

Bispecific Antibody Companies and Product Profile

• Akeso: Ivonescimab
• Zymeworks: Zanidatamab
• Roche: Glofitamab
• IGM Biosciences: Imvotamab
• MacroGenics: MGD024

Bispecific Antibody Competitive Landscape

The Bispecific Antibody competitive landscape report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

Bispecific Antibody Report Assessment

• Bispecific Antibody Company Analysis
• Bispecific Antibody Therapeutic Assessment
• Bispecific Antibody Pipeline Assessment
• Inactive drugs assessment
• Bispecific Antibody Unmet Needs

Learn more about the emerging Bispecific Antibody Competitive Landscape @ Bispecific Antibody Market Drivers and Barriers, Unmet Needs

Scope of the Bispecific Antibody Report

• Coverage- Global
• Bispecific Antibody Therapeutics Assessment: Product Type, Stage and Product Type, Route of Administration, Molecule Type
• Bispecific Antibody Companies- Janssen, Amgen, Akeso, Zymeworks, Roche, IGM Biosciences, MacroGenics, Provention Bio, Jiangsu Alphamab Biopharmaceuticals, Sichuan Baili Pharmaceutical, Regeneron Pharmaceuticals, Boehringer Ingelheim, and others.
• Bispecific Antibody Therapies- SI-B003, AK104, Bevacizumab, Paclitaxel, AK112, LY3434172, CDX-527, Etoposide, Carboplatin, and others.

Dive deep into rich insights for new drugs for Bispecific Antibody Product Developmental Activities, Visit @ Bispecific Antibody Research and Development Activities

Table of Content

1. Introduction
2. Executive Summary
3. Bispecific antibody: Overview
4. Bispecific Antibody -Analytical Perspective: In-depth Commercial Assessment
5. Competitive Landscape
6. Therapeutic Assessment
7. Bispecific antibody: Company and Product Profiles (Marketed Therapies)
8. Janssen
9. Amivantamab
10. Bispecific antibody: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Phase III)
12. Akeso
13. Ivonescimab
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II)
16. IGM Biosciences
17. Imvotamab
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. MacroGenics
21. MGD024
22. Drug profiles in the detailed report…..
23. Preclinical and Discovery Stage Products
24. Company Name
25. Product Name
26. Drug profiles in the detailed report…..
27. Inactive Products
28. Bispecific antibody- Unmet needs
29. Bispecific antibody – Market drivers and barriers
30. Appendix

For further information on the Bispecific Antibody Report @ Bispecific Antibody Preclinical and Discovery Stage Products

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/hypertriglyceridemia-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bispecific Antibody Competitive Landscape Report (Updated) | Janssen, Amgen, Akeso, Zymeworks, Roche, IGM Biosciences, MacroGenics, Provention Bio, and others.

DelveInsight’s, “Antibody Drug Conjugate Competitive Landscape, 2023,” report provides comprehensive insights about 180+ Antibody Drug Conjugate companies and 290+ Antibody Drug Conjugate drugs in Antibody Drug Conjugate Competitive landscape. It covers the Antibody Drug Conjugate pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive ADC pipeline products in this space.

Key Takeaways from the Antibody Drug Conjugate Pipeline Report

• DelveInsight’s Antibody Drug Conjugate pipeline report depicts a robust space with 180+ active players working to develop 290+ pipeline therapies for Antibody Drug Conjugate treatment.
• The leading companies working in the Antibody Drug Conjugate Market include NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc, ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA, Sorrento Therapeutics, Inc., Peak Bio, Regeneron Pharmaceuticals, Asana BioSciences, Tanabe Research Laboratories USA, OBI Pharma, Sanofi, Navrogen, Inc., and others.
• Promising Antibody Drug Conjugate Pipeline Therapies in the various stages of development include Mirvetuximab Soravtansine, Datopotamab deruxtecan, Ladiratuzumab vedotin, STI-6129, MYTX-011, M1231, NBE-002, Sacituzumab Govitecan, IMGN151, IMGC936, REGN5093-M114, ASN004, TR1801-ADC, STRO-001, OBI-999, YL201, TORL-2-307-ADC, ARX788, and others.
• December 2023: Unicancer announced a drug which is named DS-8201a in the clinical trials of phase 2. Multicenter, open-label phase II trial assessing the efficacy of DS-8201a monotherapy in patients with metastatic breast cancer.
• December 2023: Daiichi Sankyo Inc. announced a drug which is named Ifinatamab Deruxtecan (I-DXd) in the clinical trials of phase 2. This study intends to define the recommended Phase 2 dose of ifinatamab deruxtecan (I-DXd) based on the efficacy, safety, and pharmacokinetics (PK) results observed in participants with Extensive-stage Small Cell Lung Cancer (ES-SCLC) who received at least 1 prior line of platinum-based chemotherapy and a maximum 3 prior lines of therapy and to investigate I-DXd anti-tumor activity in this population.

Request a sample and discover the recent advances in Antibody Drug Conjugate Drugs @ Antibody Drug Conjugate Competitive Landscape Report

The Antibody Drug Conjugate Pipeline Report provides in-depth commercial assessment of ADC drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the Antibody Drug Conjugate pipeline report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

Antibody Drug Conjugate Overview

Antibody–drug conjugates (ADC) are one of the fastest growing anticancer drugs. This approach comprises a mAb conjugated to the cytotoxic payload via a chemical linker that directed toward a target antigen expressed on the cancer cell surface, reducing systemic exposure and therefore toxicity. ADCs are complex molecules that require careful attention to various components.

Find out more about Antibody Drug Conjugate-Analytical Perspective: In-depth Commercial Assessment @ Antibody Drug Conjugate Collaboration Analysis by Companies

Antibody Drug Conjugate Pipeline Therapies and Companies

• Jiangsu Hengrui Medicine Co Ltd.: SHR-A1811
• Seagen Inc.: Ladiratuzumab Vedotin
• ImmunoGen Inc.: IMGN151
• Daiichi Sankyo: DS-6000

Antibody Drug Conjugate Pipeline Analytical Perspective

The Antibody Drug Conjugate pipeline report provides in-depth commercial assessment of Antibody Drug Conjugate drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the Antibody Drug Conjugate pipeline report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

Antibody Drug Conjugate Pipeline Report Assessment

• Antibody Drug Conjugate Company Analysis
• Antibody Drug Conjugate Pipeline Therapeutic Assessment
• Antibody Drug Conjugate Pipeline Assessment
• Inactive Antibody Drug Conjugate drugs assessment
• Antibody Drug Conjugate Unmet Needs

Learn more about the emerging Antibody Drug Conjugate Competitive Landscape @ Antibody Drug Conjugate Market Drivers and Barriers, Unmet Needs

Scope of the Antibody Drug Conjugate Competitive Landscape Report

• Coverage- Global
• Antibody Drug Conjugate Therapeutics Assessment: Product Type, Stage and Product Type, Route of Administration, Molecule Type
• Antibody Drug Conjugate Companies- NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc, ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA, Sorrento Therapeutics, Inc., Peak Bio, Regeneron Pharmaceuticals, Asana BioSciences, Tanabe Research Laboratories USA, OBI Pharma, Sanofi, Navrogen, Inc., and others.
• Antibody Drug Conjugate Pipeline Therapies- Mirvetuximab Soravtansine, Datopotamab deruxtecan, Ladiratuzumab vedotin, STI-6129, MYTX-011, M1231, NBE-002, Sacituzumab Govitecan, IMGN151, IMGC936, REGN5093-M114, ASN004, TR1801-ADC, STRO-001, OBI-999, YL201, TORL-2-307-ADC, ARX788, and others.

Dive deep into rich insights for new drugs for Antibody Drug Conjugate Product Developmental Activities, Visit @ Antibody Drug Conjugate Research and Development Activities

Table of Content

1. Introduction
2. Antibody Drug Conjugate Executive Summary
3. Antibody Drug Conjugate Overview
4. Antibody Drug Conjugate-Analytical Perspective: In-depth Commercial Assessment
5. Antibody Drug Conjugate Competitive Landscape
6. Antibody Drug Conjugate Therapeutic Assessment
7. Antibody Drug Conjugate: Company and Product Profiles (Marketed Therapies)
8. Pfizer
9. MYLOTARG
10. Antibody Drug Conjugate: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Phase III)
12. ADC Therapeutics
13. Zynlonta
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II)
16. Seagen Inc.
17. Ladiratuzumab Vedotin
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. ImmunoGen, Inc.
21. IMGN151
22. Drug profiles in the detailed report…..
23. Preclinical and Discovery Stage Products
24. Company Name
25. Product Name
26. Drug profiles in the detailed report…..
27. Inactive Products
28. Antibody Drug Conjugate – Unmet needs
29. Antibody Drug Conjugate– Market drivers and barriers
30. Appendix

For further information on the Antibody Drug Conjugate Report @ Antibody Drug Conjugate Preclinical and Discovery Stage Products

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/hypertriglyceridemia-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Antibody Drug Conjugate Competitie Landscape Report (Updated) | ImmunoGen, Inc., Seagen Inc, ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA, and others.